Pacific Biosciences of California
Last Friday, shares in Menlo Park, California headquartered Pacific Biosciences of California Inc. ended the session 1.54% higher at $3.95. The stock recorded a trading volume of 7.34 million shares, which was above its three months average volume of 1.14 million shares. The Company's shares are trading 49.61% below their 50-day moving average. Moreover, shares of Pacific Biosciences of California, which designs, develops, and manufactures sequencing systems to resolve genetically complex problems, have a Relative Strength Index (RSI) of 14.97.
On December 15th, 2016, the Company announced that F. Hoffman-La Roche Ltd (Roche) has elected to terminate for convenience the development, commercialization and license agreement with Pacific Biosciences for the development and supply of diagnostic products based on the company's Single Molecule, Real-Time (SMRT®) technology. The agreement, which was entered into by the parties in 2013, provides the option for Roche to terminate the agreement for any reason with sixty days' prior notice. Upon termination, other than retaining certain non-exclusive rights with respect to using products already purchased from Pacific Biosciences under the agreement, Roche will have no rights to SMRT technology, and Pacific Biosciences will be free to commercialize products based on the Sequel™ sequencing platform into the clinical research and sequencing market, directly or with other distribution partners. The free research report on PACB is available at:
Milton, Canada headquartered Aralez Pharmaceuticals Inc.'s stock declined 1.22%, to close the day at $4.87. A total volume of 3.05 million shares was traded, which was higher than their three months average volume of 704,560 shares. The Company's shares are trading 2.79% and 11.53% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Aralez Pharma, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have an RSI of 48.65.
On December 15th, 2016, Aralez Pharma announced that it has entered into a rebate agreement with CaremarkPCS Health (also known as CVS Caremark), which secures formulary status for YOSPRALA™, the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and a proton pump inhibitor, omeprazole, in the US. The rebate agreement with CVS Caremark is effective immediately. The complimentary report on ARLZ can be downloaded at:
Shares in Concord, California headquartered Cerus Corp. recorded a trading volume of 1.04 million shares at the close of the last trading session, which was above their three months average volume of 901,860 shares. The stock ended the day 0.61% higher at $4.92. The Company's shares are trading below their 50-day moving average by 6.80%. Furthermore, shares of Cerus, which focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety, have an RSI of 40.15.
On November 03rd, 2016, Cerus reported product revenue of $10.2 million for Q3 2016, up 26% from the $8.0 million recognized during Q3 2015. The Company's gross margins on product revenue for Q3 2016 were 46%, compared to 31% for Q3 2015. Cerus' net loss for Q3 2016 was $14.4 million, or $0.14 per diluted share, compared to a net loss of $15.7 million, or $0.17 per diluted share, for Q3 2015. Visit us today and download our complete research report on CERS for free at:
Austin, Texas-based Pain Therapeutics Inc.'s shares finished Friday's session 0.31% higher at $0.62 with a total trading volume of 250,998 shares. The stock is trading below its 50-day moving average by 4.61%. Shares of the Company, which develops novel drugs in the US, have an RSI of 47.84.
As per a SEC filing dated December 08th, 2016, Pain Therapeutics on December 05th, 2016, sent a letter to Durect Corporation pursuant to the Development and License Agreement (DLA), dated as of December 19th, 2002, by and among the Company, Durect and Southern Biosystems, Inc., as amended, that provided Durect with formal written notice that the Company is removing, effective as of December 05th, 2016, the opioid drugs hydromorphone and oxymorphone (and only hydromorphone and oxymorphone) as licensed products under the DLA. Get free access to your technical report on PTIE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA